Core Insights - Novo Nordisk announced positive results from the REIMAGINE 2 trial, showing that CagriSema outperformed semaglutide in reducing HbA1c and promoting weight loss after 68 weeks [1][7]. Trial Overview - REIMAGINE 2 was a 68-week phase 3 trial assessing the efficacy and safety of once-weekly CagriSema, a combination of cagrilintide and semaglutide, in 2,728 adults with type 2 diabetes inadequately controlled with metformin [2][11]. - The trial compared two doses of CagriSema (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) against semaglutide (2.4 mg and 1.0 mg), cagrilintide (2.4 mg), and placebo [2][11]. Efficacy Results - CagriSema 2.4 mg/2.4 mg achieved a superior HbA1c reduction of 1.91%-points compared to 1.76%-points with semaglutide 2.4 mg, from a baseline HbA1c of 8.2% [3][4]. - Weight loss with CagriSema 2.4 mg/2.4 mg was 14.2%, significantly higher than the 10.2% observed with semaglutide 2.4 mg, with no weight loss plateau noted [3][4]. - 43% of participants on CagriSema achieved ≥15% weight loss, and 24% achieved ≥20% weight loss [3][8]. Safety Profile - CagriSema demonstrated a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [6][8]. Future Directions - Novo Nordisk plans to discuss the regulatory pathway for CagriSema with authorities, following the positive outcomes from REIMAGINE 1 and REDEFINE 3 trials [7][8].